InterAx Biotech’s Post

Curie.Bio, a biotech accelerator and investor, said Wednesday it raised $380 million to support its portfolio companies beyond the seed stage, helping advance their drugs into the clinic with Series A rounds. The Cambridge, MA-based firm has 20 therapeutics startups in its portfolio thus far, and one has so far publicly disclosed a Series A. That company, Forward Therapeutics, unveiled a $50 million Series A last November with three oral small molecules in just 18 months. Others are coming up behind it: Astoria Biologica, Decrypt Biomedicine and Differentiated Therapeutics. The firm said it invests in single-asset and platform biotechs, but each drug "must have blockbuster potential," meaning at least $1 billion in peak sales. Christoph Lengaeur, Curie chief scientific officer and co-founder, told me last November the firm sifts through about 1,000 applications a year. "There are some that are good, but you're not really excited about it or it's not for us, or it needs more work, and then there's a lot of shit out there, too, but that's OK. At least, that's how we perceive it. That doesn't mean that's the way it is. We can be wrong." #biotech #vc #venturecapital #accelerator #drugdevelopment #biotechstartups

👍🏻👍🏻 𝗣𝘂𝗯𝗹𝗶𝘀𝗵𝗲𝗱 𝗶𝗻 𝗔𝗚𝗘𝗙𝗜, 𝗡𝗼𝘂𝘃𝗲𝗹𝗹𝗲 𝗔𝗴𝗲𝗻𝗰𝗲 𝗘́𝗰𝗼𝗻𝗼𝗺𝗶𝗾𝘂𝗲 𝗲𝘁 𝗙𝗶𝗻𝗮𝗻𝗰𝗶𝗲̀𝗿𝗲, 𝗮𝗻 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝘀𝗵𝗼𝘄𝘀 𝘁𝗵𝗮𝘁 𝟮𝟬𝟮𝟰 𝗶𝘀 𝗮 𝗽𝗿𝗼𝗺𝗶𝘀𝗶𝗻𝗴 𝘆𝗲𝗮𝗿 𝗳𝗼𝗿 #𝗯𝗶𝗼𝘁𝗲𝗰𝗵. 🚀 Stefan Catsicas and Thomas Heimann, MSc emphasize the importance of understanding the #development phases of biotech companies, and of being discerning about the use of funds raised. They also advise focusing on M&A rather than IPOs. 💡Segments such as #oncology, severe #autoimmune diseases and #genomics are identified as promising, with a particular interest in #microbiome technologies and #longevity. BioAlps - Life Sciences Cluster 🇨🇭 Promotion économique Valais Swiss Biotech Association

Late-stage fundraising in life sciences remains extremely challenging. So, how do you raise a €100 mio Series C as a European biotech in current markets? How do you convince a new investor to invest for the first time in your Series C round? Thank you Tim Knotnerus, CEO of Agomab Therapeutics , and Felice Verduyn - van Weegen, Partner at EQT Life Sciences, for addressing these and many other questions about Agomab’s recent Series C financing round during LifeScience ORG’s Mastermind: * Fund when you can and not only when you have to; * Focus on your most relevant investors; * Continuously invest and build your most important investor relationships, even if they are not (yet) ready to invest; * Kick off your U.S. investor strategy as early as possible; * As the CEO, consider the unconventional and then lead with conviction. Masterminds are informal peer-to-peer CEO conversations where our members share and discuss relevant transaction and other experiences. Join the conversation at www.lifescienceorg.com Oliver Uecke, Miquel Vila-Perello, Oscar Izeboud, Kristof Vercruysse, Kristoffer Famm, Tom Weaver, Juliane Bernholz, Marc Gitzinger, Camilla Easter, Robert Habib, Katrien Reynders, Clive Dix.HonFBPhS, Dr. Rüdiger Jankowsky, Hanne Callewaert, Simon Skjøde Jensen, Andrew Bruce, Neil Torbett, Prof Dr Arndt Rolfs, Ola (Aleksandra) Wlodek, Maximilien Levesque, Alexandre Reeber, Nawal Ouzren, #biotechnology #lifescience #ceo #fundraising

Dear Friends and Colleagues, I am thrilled to announce that Cytonics Corporation is launching an equity #crowdfunding campaign and is now accepting shareholder reservations! Please visit our StartEngine profile page to learn more about this opportunity and stay informed as our campaign goes live: https://lnkd.in/eRTJH4P6 Since 2006, Cytonics has been on a mission to eradicate #osteoarthritis once and for all. This debilitating joint disease affects over 600M people worldwide, and there are no effective treatment options that actually address the root molecular cause of the disease. Palliative measures don't cut it, and we believe that we have the solution... a blood protein called "A2M." Why Invest in Cytonics? 🧬 Pioneering Technology: CYT-108, based on our proprietary A2M technology, has shown promising results in preclinical studies, positioning us at the forefront of innovation in the regenerative medicine sector. 📊 Massive Market Potential: Osteoarthritis affects millions globally, and the market for an effective treatment is vast and growing (>$200B globally) 🏆 Proven Track Record: Our first product, the APIC therapy, has already demonstrated the clinical efficacy and commercial viability of our approach. 🌍 Humanitarian Mission: You're not just funding a company; you're supporting a vision to revolutionize healthcare for millions suffering from joint pain and mobility issues. ❤️ Join us on our mission to rid the world of osteoarthritis once and for all. Appreciatively, Joey Bose President and CEO Cytonics #biotechnology #investing #venturecapital NO MONEY OR OTHER CONSIDERATION IS BEING SOLICITED, AND IF SENT IN RESPONSE, WILL NOT BE ACCEPTED. NO OFFER TO BUY THE SECURITIES CAN BE ACCEPTED AND NO PART OF THE PURCHASE PRICE CAN BE RECEIVED UNTIL THE OFFERING STATEMENT IS FILED AND ONLY THROUGH AN INTERMEDIARY’S PLATFORM. AN INDICATION OF INTEREST INVOLVES NO OBLIGATION OR COMMITMENT OF ANY KIND. "RESERVING" SECURITIES IS SIMPLY AN INDICATION OF INTEREST.

A great tracking resource from Labiotech.eu summarizing significant fundraising events in biotech for 2024: from Seed to Series E, PIPE, IPOs, and post-IPO equity fundings and debts. Explore the latest funding events chronologically and by method! #investment #privateequity #venturecapital #biotech #lifesciences

For #cellandgenetherapy and #orphandrugs Biotechs looking for investment, the challenges of 2023 are now behind us 👏 In 2024 the ongoing economic challenges that are preventing early stage #atmp and #orphandrug biotechs from securing the important funding they need to survive and progress means that our completely unique risk-sharing model is becoming more needed than ever to ensure the optimal chances of #fundraisingsuccess for our partners and clients. Thanks to Mark Beards, Damian Marron, Miguel Forte, Michèle Bartouilh-Neugebauer, Sonya M., Ian Hollingsworth and all those that have supported and advocated for our weird but wonderful, risky but required, frightening but fun business model for helping us to design and build what we know will be a hugely impactful service to our sector throughout 2024. We look forward to making a real difference to patients and shareholders alike during the coming year by supporting the #biotechnology organisations working hard to provide innovative therapies to our community. Wishing everyone in the #cellandgenetherapies and #rarediseases communities the very best for the year ahead!

🕛ONE Week Left to Invest in Our Breakthrough Biotech 🖇 invest.cytonics.com Since 2006, Cytonics has been leading the charge in developing groundbreaking therapies for osteoarthritis. With the steadfast support of our investors, we have successfully raised over $25 million, pushing our innovative CYT-108 therapy into Phase 1 human clinical trials. We invite you to join us on our mission to rid the world of osteoarthritis, once and for all. With 1 week remaining (campaign ends August 25 at 11:59pm PST / August 26th at 2:59am EST), seize the chance to join over 6,000 dedicated shareholders committed to eradicating osteoarthritis, once and for all. This is more than an investment in a breakthrough biotech; it's an investment in the improvement of human health and well-being for generations to come. #biotechnology #drugdevelopment #clinicaltrials #arthritis #regenerativemedicine #investing #crowdfunding

The biggest mistake Biotech founders and leaders make in fundraising? It's this.... This is something that's coming up on almost every episode of The Other Side of The Table, so if you're raising money right now or about to start, it's worth taking a moment to listen to what Lee Lindley of Mercia Ventures has to say on this. And to listen to the full episode, head over to https://lnkd.in/eyx2Csmq #biotech #techbio #healthtech #biotechnology #venturecapital #vcfunding #seedfunding #seriesa #seriesb #drugdiscovery #drugdevelopment

🔥 New Biotech Launch Alert! 🔥 A cutting-edge biotech company focused on inflammatory diseases has launched with an impressive $168M in funding! 🎉🧬 Leading this innovative venture is a former Kite leader, bringing a wealth of expertise and experience to the table. 🌟 Key investors in this venture include Atlas Venture, Omega Funds, and F-Prime Capital, whose support underscores the significant potential of this new company. 💡💰 With this substantial investment, the company is poised to develop groundbreaking treatments for inflammatory conditions, aiming to make a significant impact on patient care and outcomes. 🩺 #Biotech #InflammatoryDisease #HealthcareInnovation #FundingNews #BiotechLaunch #MedicalAdvancements #InnovationInHealthcare #ScientificResearch #Biopharma #NewBeginnings #AtlasVenture #OmegaFunds #FPrimeCapital

Proud to be part of it! #Fightantimicrobialresistance BIOASTER INCATE #antibiotics INCATE marks its third anniversary of successfully supporting innovators fighting antimicrobial resistance https://lnkd.in/eEpXjP9F About INCATE INCATE is a not-for-profit partnership which brings together translational and basic research, industry, experienced entrepreneurs, and investors from across Europe and beyond. The German Center for Infection Research (DZIF), the Leibniz:HKI (part of Leibniz Association) in Germany, the Swiss National Centre of Competence in Research AntiResist, the University of Basel, are the academic founding members of INCATE, with the University of Basel acting as the host. Together with the four industry partners Boehringer Ingelheim, MSD, Roche, and Shionogi, the Technology transfer organization BIOASTER in France, and US-based venture capital firm Kineticos AMR Accelerator Fund, as well as other organizations, funders and investors, INCATE aims to ensure that the pipeline of new antibiotics and technology platforms is filled and strengthened.